TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
UK sales of hair-loss products grew 32% in the year to the end of August, according to Worldpanel by Numerator, as household use of GLP-1 medicines rose. A recent study in the British Medical Journal identified an association between GLP-1 drugs and hair loss, though researchers described the absolute risk as low. Novo Nordisk has announced plans to enter the hair-loss treatment market.
UK hair-loss product sales rose 32% in the year to the end of August, according to Worldpanel by Numerator, as household use of GLP-1 medicines increased and research reported a link between the drugs and hair loss. Novo Nordisk, the maker of Ozempic, has also announced plans to enter the hair-loss treatment market, marking a new commercial development in a category already expanding beyond traditional hair care.
Worldpanel by Numerator estimates that hair-loss products in the UK grew by 32% in the year to the end of August. The source report says sales growth likely correlates with increased GLP-1 use, but does not establish that the medicines caused the increase in product purchases. It also does not specify the product categories included in the sales estimate or provide a comparison with other markets.
The report cites household use of GLP-1 drugs in Great Britain rising from 2.3% in 2024 to 4.1% in 2025 and 6.3% in 2026, according to Worldpanel by Numerator. These figures describe the share of households, not the percentage of individuals taking the medicines. The drugs named include semaglutide and tirzepatide products such as Ozempic, Wegovy and Mounjaro.
A recent study published in the British Medical Journal identified an association between GLP-1 drugs and increased risk of hair loss. The researchers described the absolute risk as low, according to the report. Novo Nordisk’s announced intention to enter the hair-loss treatment arena is another sign of the market’s growing commercial attention; details of its planned treatments were not provided in the available report.
Rising Demand Meets Drug-Safety Questions
The development links two issues that matter to consumers: the expanding use of medicines for weight management and concern about unwanted effects that may affect appearance. People experiencing hair loss while using a GLP-1 drug may seek information or products, while retailers and manufacturers may respond to rising demand. However, the sales figures do not show that GLP-1 use alone is driving purchases, and they do not establish that hair-loss products address a drug-related cause.
The BMJ study’s reported association adds evidence to a discussion that the source says had previously been largely anecdotal. Its low absolute-risk finding is relevant: an association does not mean that most users will experience hair loss, nor does it on its own establish that the medicine caused an individual’s symptoms. The report says awareness of the potential effect may inform treatment decisions.
Novo Nordisk’s move could bring a major medicine company into a field that includes products promising thicker, stronger or fuller-looking hair, as well as treatments for loss and thinning. Its announcement signals commercial interest, but the available details do not establish what products it will offer, when they may arrive or what evidence will support any treatment claims.
Products Worth Considering
Therabody SmartGoggles 2nd Gen Heated Eye and Temple Massager
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Navy
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
As an affiliate, we earn on qualifying purchases.
From Hair-Care Claims to GLP-1 Use
Products marketed for volume, thickness and strength, along with treatments for hair loss and thinning, were already established categories before the recent rise in GLP-1 use. The change described in the Cosmetics Business report is the growing potential customer base and the increased attention to hair loss in connection with widely used medicines.
Worldpanel by Numerator’s figures show a steady rise in the share of Great British households using GLP-1 drugs across the three reported years: 2.3% in 2024, 4.1% in 2025 and 6.3% in 2026. Separately, its estimate of hair-loss product growth covers the year to the end of August. Those are different measures and periods; the report offers no detailed analysis proving one trend caused the other.
The report describes the BMJ publication as new research that adds to earlier anecdotal reports. It does not provide the study’s sample size, methods, specific risk estimates or details about which medicines and patients were included, limiting what can be concluded from the excerpt alone.
“The absolute risk is low.”
— Researchers in the BMJ study, as summarized by Cosmetics Business
Cause, Risk and Product Plans Remain Open
The available report does not establish that GLP-1 medicines caused the UK sales increase in hair-loss products. The figures show parallel developments, and the source describes their relationship as a likely correlation. It gives no evidence about why consumers bought the products or whether they were using GLP-1 drugs.
Details of the BMJ study are limited in the source excerpt. The exact size of the increased risk, which patients or medicines were studied, and how researchers accounted for other possible causes of hair loss are not stated. The association therefore cannot be treated as proof that a GLP-1 medicine caused hair loss in any particular person.
Novo Nordisk’s planned entry is also short on specifics: no treatment name, formulation, development stage, launch date or supporting clinical data is included. It is not clear how the company’s plans relate to the products already sold for thinning or hair loss.
Study Details and Company Plans
Further details from the BMJ study would help readers understand the scale and limits of the reported association, including the absolute risk and the population studied. People concerned about hair loss while taking a prescribed medicine can raise it with their healthcare professional rather than changing or stopping treatment on their own.
For the market, the next developments to watch are whether Worldpanel by Numerator publishes further sales data and whether Novo Nordisk shares details of its hair-loss plans. Until then, the reported sales growth and company intention indicate increasing attention to the category, but not a confirmed launch or proof that GLP-1 use explains the demand.
Key Questions
Did UK sales of hair-loss products increase?
Yes. Worldpanel by Numerator estimates a 32% increase in UK hair-loss product sales in the year to the end of August. The report does not give a product breakdown or specify the comparison baseline beyond that stated growth.
Does the BMJ study prove GLP-1 drugs cause hair loss?
No. The source says the study identified an association with increased risk, not proof of causation. It also reports that the researchers described the absolute risk as low.
How common is GLP-1 use in Great Britain?
Worldpanel by Numerator put household use at 2.3% in 2024, 4.1% in 2025 and 6.3% in 2026. These figures refer to households, not the proportion of individual people taking the medicines.
What has Novo Nordisk announced?
The company has announced an intention to enter the hair-loss treatment market. The report does not state what products it plans to develop or when they could become available.
Source: rss
